NovoCure: Undervalued Stock with Potential for Significant Growth

NovoCure's share price has declined 38.8% over the last year and 91.3% over 5 years. The stock scores a 5 out of 6 valuation check, with a Discounted Cash Flow analysis suggesting it is 92.9% undervalued. The model projects free cash flows out to 2030, with estimates rising from $58.9 million in 2026 to $699 million in 2030.